Plan B One-Step Shortage: What Providers and Prescribers Need to Know in 2026

For clinical providers — OB/GYNs, family medicine physicians, NPs, PAs, and urgent care clinicians — emergency contraception access questions arrive regularly. Patients are confused about availability, whether Plan B One-Step is in a shortage, and what to do when they can't find it. This guide gives clinicians the current facts and practical talking points for 2026.

Current Availability Status of Plan B One-Step (2026)

Plan B One-Step (levonorgestrel 1.5 mg) is not on the FDA's current drug shortage list. Teva Pharmaceuticals produces the brand-name product, and multiple generic manufacturers supply equivalent formulations. National supply is stable.

That said, local pharmacy stock can still be depleted — particularly after demand spikes tied to social or political events, in rural areas with limited pharmacy coverage, and at smaller independent pharmacies that carry minimal OTC inventory. Providers should be prepared to counsel patients about alternatives when levonorgestrel EC is temporarily unavailable locally.

Emergency Contraception Overview: Clinical Reference

Plan B One-Step and its generics contain levonorgestrel, a synthetic progestin. The mechanism of action is primarily inhibition of ovulation through blockade of the LH surge. It also thickens cervical mucus. It does not terminate an established pregnancy.

Dosage: 1.5 mg levonorgestrel as a single oral dose, taken as soon as possible within 72 hours of unprotected intercourse

Efficacy: Reduces pregnancy risk by 75–89% when taken within 72 hours; reduces expected pregnancy rate from ~8% to ~1.1% per clinical trial data

FDA approval: Originally approved 1999 (Plan B); Plan B One-Step approved 2009; OTC without age restriction since June 2013

Controlled substance: No — levonorgestrel is not a scheduled substance

OTC status: Available without prescription or ID at pharmacies and many retailers; no age restriction

Weight and BMI Considerations: A Critical Clinical Point

Evidence indicates that levonorgestrel EC may have reduced efficacy in patients with higher BMI:

BMI 26–29: Possibly reduced efficacy; counsel patient and consider alternatives

BMI ≥30 / weight >165 lbs: Levonorgestrel likely ineffective; strongly consider ella or copper IUD

BMI ≥35: Copper IUD is the recommended option; ella also has reduced (but not absent) efficacy at this BMI range

Emergency Contraception Alternatives: Clinical Overview

When Plan B One-Step or generic levonorgestrel is unavailable or contraindicated:

ella (ulipristal acetate 30 mg): Prescription required; effective up to 120 hours; superior efficacy at higher BMIs (up to ~35); do not use if patient has taken hormonal contraceptives in the last 5 days; $40–$68 without insurance; widely covered under ACA

Copper IUD (ParaGard): Most effective EC (>99%); insert within 5 days; BMI-independent; also provides up to 10 years ongoing contraception; requires in-office placement; covered by most ACA-compliant plans

Levonorgestrel IUD (Mirena, Liletta — off-label EC): Evidence-supported for EC use within 5 days; provides 3–8 years of ongoing contraception; appropriate for patients who want long-term contraception

Key Drug Interactions to Counsel Patients About

The following medications and herbal products reduce levonorgestrel plasma concentrations via CYP3A4 induction and may significantly impair efficacy:

Rifampin (rifampicin) — strongest interaction; significant reduction in levonorgestrel AUC

Anticonvulsants — carbamazepine, phenytoin, phenobarbital, oxcarbazepine, topiramate, felbamate

Efavirenz (HIV antiretroviral) — reduces levonorgestrel AUC by ~50%

St. John's Wort — herbal CYP3A4 inducer; clinically significant reduction in progestin levels

Griseofulvin (antifungal) — moderate interaction

For patients on any of these medications, the copper IUD is the recommended alternative EC method.

Insurance and Cost Considerations for Patients

Under the ACA, most private health plans are required to cover FDA-approved emergency contraceptives without cost-sharing when prescribed. However, since Plan B One-Step is OTC, patients buying it without a prescription at the counter may not have it covered automatically. Writing a prescription for levonorgestrel EC (or ella) can help patients get insurance coverage.

Plan B One-Step brand: ~$45–$50 OTC cash price

Generic levonorgestrel EC: $11–$45 OTC; with GoodRx from $12.27

ella: ~$40–$68 without insurance; often covered by insurance when prescribed

All products are FSA/HSA-eligible

How medfinder Supports Your Patients' Access

When patients can't find Plan B One-Step or a generic at their pharmacy, medfinder for providers offers a solution: patients enter their medication, dosage, and location, and medfinder calls pharmacies in their area to ask which ones have it in stock. Results are texted directly to the patient. This removes the burden of patient-initiated pharmacy searching and can be especially valuable for patients in time-sensitive situations.

Advance Counseling: Proactive Prescribing

Clinical guidelines support discussing emergency contraception in advance of need — sometimes called "advance provision." Patients who have a levonorgestrel EC at home can use it immediately after a failure, maximizing efficacy. Writing a prescription for ella in advance is also an option for patients who prefer it or who may have reduced efficacy with levonorgestrel due to body weight.

For more on guiding your patients, see our detailed provider resource: How to help your patients find Plan B One-Step in stock: a provider's guide.